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Abstract 
In oncology practice, the human body surface area (BSA) is used for 
the calculation of the dose of chemotherapy. The human BSA is determined 
by derived formulas, but it is not directly linked to the pharmacokinetics of 
the drugs. Obesity alters the disposition of drugs pharmacokinetics, which 
should be considered when prescribing medications in this patient 
population. Failure to adjust doses in obesity may result in increased toxicity. 
The aim of this study was to assess predictors of an increase in the level of 
trygliceride considered to be among the cardiovascular risk factors. 
Method. The study involved 118 oncology patients with various tumor 
localizations. The patients underwent anthropometric measurements (height, 
weight, circumference, fat fold thickness, the distance between the 
epicondyls above the joint), and the BSA (according to the Mosteller 
formula). Patients who received cisplatin chemotherapy were analyzed in 
serum triglyceride levels before and after the treatment. 
Results. A comparison of female and male subsamples revealed no 
significant in variance between sexes and no significant differences in initial 
triglyceride, triglyceride change, and in the age between groups. Body fat 
mass was relatively higher in females, while body muscle mass and bone 
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mass were relatively higher in males. There was a difference in the cisplatin 
dose, with a higher dose for males than for females. The results demonstrate 
that the higher cisplatin dose and higher body fat mass are significant 
predictors of an increase in triglyceride for both sexes.  
 
Keywords:  Body surface area (BSA), chemotherapy, cisplatin, body fat 
mass, triglycerides  
 
Introduction: 
Platinum-based drugs are widely used anticancer agents with a broad 
range of antitumor activities. Cisplatin [cis-diamminedichloroplatinum(II)] 
has a significant activity in ovarian, testicular, colon, bladder, head and neck, 
and lung cancer, where it is most commonly used in combination with other 
drugs (Loehrer & Einhorn, 1984); (Yoon et al., 2011). A cytotoxic drug 
appears to have alkylation action and to possess antitumor activity. Thus, it 
has become one of the most successful anticancer drug used worldwide in 
almost 50% of solid tumor chemotherapies. One of the major problems of 
antineoplastic chemotherapy refers to the high toxicity of antitumor drugs. In 
order to reduce their negative influence on healthy cells of a body and 
enhance the efficacy of therapy (Yaroshenko, Grigoriev, Sidorova & 
Kartsova, 2013). Although the initial response rates can be high with 
cisplatin-based regimen, the clinical utility of the drug is often limited by the 
onset of acquired or intrinsic resistance (Wang & Lippard, 2005) and the 
number of side effects such as kidney damage, vomiting/nausea, and 
neurotoxicity. 
 With approximately one-third of Americans now being obese (as 
defined by a body mass index, or BMI, ≥30 kg/m2) (Flegal, Carroll & 
Ogden, 2010), by determining appropriate methods for dosing chemotherapy 
in obese patients, it is important to ensure safe and effective cancer care for 
an increasingly large segment of the population (Hourdequin, Schpero, 
McKenna, Piazik & Larson, 2013). In adult patients with cancer, drug dosing 
has traditionally been based on a patient’s estimated body surface area 
(BSA) (Freireich, Gehan & Rall, 1966). The most commonly used Mosteller 
formula for BSA calculation was also used in this study. 
 There exists a compelling evidence that reductions from a standard 
dose and dose-intensity may compromise disease-free survival (DFS) and 
overall survival (OS) in the curative setting (Lyman, 2011). Furthermore, a 
number of authors have suggested that the optimal delivery of cancer 
chemotherapy should be considered an indicator of quality of care (Griggs,  
et al., 2012). 
 Since 1950’s, researchers have used body surface area (BSA), a 
number determined by a person’s height and actual body weight (ABW). 
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 Problems arise when patients are obese, as dose calculations based on 
BSA can be very high. Many practitioners, fearing excess toxic effects with 
such large doses, respond by reducing the doses of chemotherapy given to 
obese patients. Clinical practice varies significantly, both in terms of whether 
doses are reduced and, if so, how this is done (Griggs, Sorbero & Lyman, 
2005); (Lyman, 2011). 
The obesity has been associated with poorer survival in many 
cancers, including breast, colon, ovarian, and prostate cancers (Efstathiou, 
Bae & Shipley, 2007); (Lu, Ma & Malone, 2011); (Meyerhardt, Catalano & 
Haller, 2003); (Boyd, Campbell & Germanson, 1981); (Newman, Lees & 
Jenkins, 1997); (Zhang, Xie & Lee, 2005); (Pavelka, Brown & Karlan, 
2006); (Litton, Gonzalez-Angulo & Warneke, 2008); (de Azambuja, 
McCaskill-Stevens & Francis, 2010). While this poorer survival is 
multifactorial, there is some evidence to suggest that chemotherapy under 
dosing in obese patients may be contributing to these worse outcomes. 
Regardless of body weight, reducing the dose intensity of chemotherapy has 
been shown to negatively impact survival in multiple cancer types (Wildiers 
& Reiser, 2011); (Wood, Budman & Korzun, 1994); (Bonadonna & 
Valagussa, 1981). Despite studies confirming the safety and importance of 
full weight– based cytotoxic (intravenous [IV] and oral) chemotherapy 
dosing, many overweight and obese patients continue to receive limited 
chemotherapy doses (Lyman, Dale & Crawford, 2003); (Greenman, Jagielski 
& Griggs, 2008); (Griggs & Sabel, 2008); (Griggs, Sorbero & Lyman, 2005). 
 Practice pattern studies demonstrate that up to 40% of obese patients 
receive limited doses that are not based on actual body weight. 
A triglyceride (TG, triacylglycerol, TAG, or triacylglyceride) is an 
ester derived from glycerol and three fatty acids (IUPAC-IUB Commission 
on Biochemical Nomenclature (CBN), 2007). As a blood lipid, they help 
enable the bidirectional transference of adipose fat and blood glucose from 
the liver. There are many triglycerides: depending on the oil source, some are 
highly unsaturated, some so. Triglycerides are formed by combining glycerol 
with three molecules of fatty acid. Fat and liver cells can synthesize and store 
triglycerides. When the body requires fatty acids as an energy source, the 
hormone glucagon signals the breakdown of the triglycerides by hormone-
sensitive lipase to release free fatty acids.  
 Triglycerides cannot pass through cell membranes freely. Special 
enzymes on the walls of blood vessels, called lipoprotein lipases, must break 
down triglycerides into free fatty acids and glycerol. Fatty acids can then be 
taken up by cells via the fatty acid transporter (FAT). 
 In the human body, high levels of triglycerides in the bloodstream 
have been linked to atherosclerosis and, by extension, the risk of heart 
disease and stroke. The relative negative impact of raised levels of 
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triglycerides compared to that of Low-density lipoprotein (LDL): high-
density lipoprotein (HDL) ratios are as yet unknown. The risk can be partly 
accounted for by a strong inverse relationship between triglyceride level and 
HDL-cholesterol level. Triglycerides are considered to be among the 
cardiovascular risk factors (Strumberg et. al., 2002). 
 Therefore, control for triglycerides in the blood during the treatment 
seems an important feature for understanding pharmacokinetics of drugs. At 
the same time, anthropometry allows to assess body muscle, bone and fat 
mass. Taking into account an opportunity provided by anthropometric 
methods, the aim of this study was to assess body muscle, bone, and fat 
mass, a dose of cisplatin, and an initial triglyceride level as predictors of an 
increase in the level of triglycerides (Table 1.).  
Table 1. Criteria proposed for clinical diagnosis of elevated triglyceride 
levels under fasting conditions (Berglund et. al., 2012) 
NCEP ATP III(a)            The Endocrine Society 2010(b) 
Normal <150 mg/dl 
<1.7 
mmol/liter Normal <150 mg/dl 
<1.7 
mmol/liter 
Borderline-high 
triglycerides 
150–199 
mg/dl 
1.7–2.3 
mmol/liter 
Mild 
hypertriglyceridemia 150–199 mg/dl 
1.7–2.3 
mmol/liter 
High 
triglycerides 
200–499 
mg/dl 
2.3–5.6 
mmol/liter 
Moderate 
hypertriglyceridemia 200–999 mg/dl 
2.3–11.2 
mmol/liter 
Very high 
triglycerides 
≥500 
mg/dl 
≥5.6 
mmol/liter 
Severe 
hypertriglyceridemia 
1000–1999 
mg/dl 
11.2–22.4 
mmol/liter 
   Very severe hypertriglyceridemia ≥2000 mg/dl 
≥22.4 
mmol/liter 
aNCEP ATP III - National Cholesterol Education Program Adult Treatment Panel 
bThe criteria developed for the present guidelines focus on the ability to assess risk for 
premature CVD (cardiovascular disease) vs. risk for pancreatitis. The designations of mild 
and moderate hypertriglyceridemia correspond to the range of levels predominant in risk 
assessment for premature CVD, and this range includes the vast majority of subjects with 
hypertriglyceridemia. Severe hypertriglyceridemia carries a susceptibility for intermittent 
increases in levels above 2000 mg/dl and subsequent risk of pancreatitis; very severe 
hypertriglyceridemia is indicative of risk for pancreatitis. In addition, these levels suggest 
different etiologies. Presence of mild or moderate hypertriglyceridemia is commonly due to 
a dominant underlying cause in each patient, whereas severe or very severe 
hypertriglyceridemia is more likely due to several contributing factors. 
 
Methods: 
The study involved 118 oncology patients.There were 34 females 
aged from 42 to 79 years (median age 64 years) and 84 males aged from 28 
to 84 (median age 65 years). The median age of patients at the time of our 
study was 64 years. The sample consisted of patients with cancer of any 
type, receiving chemotherapy based on BSA. BSA was calculated in 
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accordance with the Mosteller formula:  BSA (m2) = [Ht(cm) * Wt(kg) / 
3600 ]½, where Ht - height (cm), Wt- body weight (kg). 
The body mass index, defined as body weight (kg) divided by height 
squared (m2), was used as a measure of obesity.  We included patients who 
met the criteria: reported according to obese (BMI ≥30 kg/m2) and normal 
weight (BMI 18.5–24.9 kg/m2) categories, as defined by the 1995 WHO 
criteria (Cole, Bellizzi, Flegal, & Dietz, 2000). In our study, 5% of patients 
had a BMI below 18.5kg/m2, 40% of the normal weight range, but 31% of 
25-30 kg/m2 and 24% of cases of obesity (over 30 kg/m2). 
Anthropometry: Body anthropometric parameters in cancer patients 
were used as scales, measuring tapes, anthropometers (gauge height) and 
calliper. 
Adipose tissue (passive) mass of the formula: 
( )
12100
160(1003,1 654321 ddddddHWD +++++×−++×=    (1) 
where: D - fat mass (kg), W – body weight (kg), H – height (cm), d – fat fold 
thickness (mm) on the upper arm, forearm, thigh, lower leg, the ribs and 
abdomen. 
Active muscle mass of the formula: 
3
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where: M - muscle mass (kg), E4 lower arm + forearm + Upper + Lower the 
amount of girth (cm), E5 fat fold  - 5 fold the amount of fat (2  arm + 
forearm + Upper + Lower) (mm), H - height (cm)   
Bone mass of: 
3
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where: O – bone mass (kg), H - height (cm) E4epi - the distance between 
epicondil amount (arm epicondil + forearm + Upper + Lower) (cm).   
Adipose tissue, muscle, bone mass determination in relative terms 
(%) was carried out according to the formulas: 
W
100D = mass(%)    tissueAdipose ×     (4) 
W
100M = mass(%)  Muscule ×                                                              (5)
 
W
100O = (%) mass  Bone ×                                                                (6) 
where: W- body weight (kg)  
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The Medium build body tissue composition in relative terms (%) is 
given in Table 2.  
Table 2. Medium build body tissue composition in relative terms (%) 
 
In patients who received cisplatin (75 mg/m2) chemotherapy was 
analyzed in serum triglyceride levels before and after treatment. All blood 
samples and triglycerides were analyzed according to laboratory standards at 
Pauls Stradins University Hospital and standard normal ranges were used in 
patients receiving of cisplatin after intravenous (i.v.) administration. 
 
Results: 
In order to assess predictors of triglyceride change in the research 
sample, the analysis was performed in three steps: a comparison of female 
and male subsamples, correlation analysis, and a regression analysis. 
 Table 3 presents descriptive statistics and comparison of means in 
females and males.  
Table 3. Descriptive statistics and comparison of means between sexes 
*** p< 0.001. ** p<0 .01. * p<0 .05. 
 
 It should be noted that Levene’s test for equality of variations 
demonstrated no significant differences in variance between sexes. Student’s 
t-test demonstrated no significant differences in initial triglyceride, 
triglyceride change, and in age between groups. Body fat mass was higher in 
females, when body muscle mass and bone mass were higher in males. In 
addition, there was a difference in the cisplatin dose, with a higher dose for 
males than for females (p < 0.001). 
 Pearson product-moment correlations indicated positive correlations 
of change of triglyceride with the cisplatin dose, initial level of triglyceride 
Gender Adipose tissue mass Muscule mass Bone mass 
Male 12.63 -16.29 32.91 – 35.18 10.77 – 12.88 
Female 19.60 -24.21 23.69 – 25.64 8.64 – 9.61 
 Males (n = 84) Females (n = 34)  
Measures M (SD) M (SD) t-test 
Age, years 62.51 (11.16) 62.68 (10.23) -0.07 
Fat mass 10.85 (4.77) 14.27 (5.04) -3.43** 
Muscle mass 28.27 (5.52) 25.23 (6.20) 2.61* 
Bone mass 13.53 (1.67) 10.40 (1.41) 9.59*** 
Cisplatin dose (mg) 130.30 (21.08) 122.21 (14.83) 2.04* 
Initial triglyceride (mmol/l) 1.22 (0.39) 1.19 (0.32) 0.28 
Change of triglyceride(%) 0.58 (0.44) 0.52 (0.39) 0.66 
European Scientific Journal February 2015 edition vol.11, No.6 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
17 
and body fat, muscle, and bone mass (p<0.001) (Table 4). At the same time, 
there were no significant correlations between the change of triglyceride and 
age or sex. 
Table 4.Correlations among triglyceride, cisplatin dose, anthropometric measures, age, and 
sex (n = 118). 
 1. 2. 3. 4. 5. 6. 7. 8. 
1. Change of 
triglyceride 
-        
2. Cisplatin dose 0.50*** -       
3. Initial triglyceride 0.32*** 0.45*** -      
4. Fat mass 0.47*** 0.16 0.41*** -     
5. Muscle mass 0.48*** 0.33*** 0.52*** 0.60*** -    
6. Bone mass 0.34*** 0.24* 0.39*** 0.17 0.64*** -   
7. Age -0.15 -0.23* -0.12 -0.03 -0.22* -0.07 -  
8. Sex -0.06 -0.19* -0.03 0.31** -0.24* -0.67*** 0.01 - 
Note. Males and females were coded as 1 and 2, respectively.  
*** p< 0.001. ** p<0.01. * p<0 .05. 
 
To answer the question about the predictors of a toxic effect, a 
standard multiple linear regression was performed with a change of 
triglyceride as an independent variable and the cisplatin dose (p <0.001), 
initial triglyceride, body fat mass, muscle mass, and bone mass as dependent 
variables. Despite the absence of a significant correlation, sex was included 
into analysis as a dependent variable in order to control its effect on the 
model. Table 5 displays regression coefficients and an evaluation of the 
model. 
Table 5. Standard multiple linear regression of triglyceride change on the cisplatin dose, 
initial triglyceride, sex, body fat, muscle, and bone masses (n=118) 
Predictors B SEB β 
Cisplatin dose 0.01 0.00 0.43*** 
Initial triglyceride -0.18 0.10 -0.16 
Fat mass 0.03 0.01 0.31** 
Muscle mass 0.02 0.01 0.20 
Bone mass 0.03 0.03 0.14 
Sex 0.03 0.11 0.03 
Model: F (6, 112) = 15.94, p < 0.001; R2 = 0.47, adjusted R2 =0 .44. 
*** p< 0.001. ** p<0 .01. 
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The higher cisplatin dose contributed significantly to the increase of 
triglyceride. Higher body fat mass also predicted an increase of triglyceride. 
Body muscle mass, bone mass, initial triglyceride, and sex did not contribute 
significantly to the model. 
 
Discussion: 
The results demonstrate that the higher cisplatin dose and higher 
body fat mass are significant predictors of an increase in triglyceride. In our 
study, taking into account the American Heart Association guidelines 
triglyceride levels corresponded to slightly above normal. Since patients are 
receiving chemotherapy courses, increase in triglycerides can be predicted 
with each subsequent cisplatin in patients with excess body weight. 
Obesity increases the risk of multiple disease states including 
hypertension, diabetes mellitus, and coronary artery disease (Polk, 2005). 
The comorbidities, frequently associated with obesity, result in the need for 
numerous medications to manage these conditions. Obesity alters the 
disposition of drugs in the body (pharmacokinetics), which should be 
considered when prescribing medications in this patient population. Failure 
to adjust doses in obesity may result either in therapeutic failure or increased 
toxicity.  
Some importance during therapy is to diet. Diets high in refined 
carbohydrates, with carbohydrates accounting for more than 60% of the total 
energy intake, can increase triglyceride levels (American Heart Association 
(AHA), 2014, April 21). Of note is how the correlation is stronger for those 
with higher BMI (28+) and insulin resistance (more common among the 
overweight and obese patients) is a primary suspect cause of this 
phenomenon of carbohydrate-induced hypertriglyceridemia (Parks, 2002). 
Those with a body mass index (BMI) equal to or greater than 28 kg/m2 
experienced a 30% increase in TAG concentration, while those whose BMI 
was less than 28, experienced no change...These data demonstrate that 
certain characteristics (e.g., BMI) can make some individuals more sensitive 
with respect to lipid and lipoprotein changes when dietary CHO is increased. 
Such characteristics that have been identified from previous work in this 
field and include BMI, insulin sensitivity (Coulston, Hollenbeck, Swislocki 
& Reaven, 1989), concentration of TAG before the dietary change is made 
(Parks et. al., 2001), hormone replacement therapy (Kasim-Karakas, 
Almario, Mueller & Peterson, 2000), and genetic factors (Dreon, Fernstrom, 
Williams & Krauss, 2000). There is evidence that carbohydrate consumption 
causing a high glycemic index can cause insulin overproduction and increase 
triglyceride levels in women (Andrew Weil, 2003, September 22). Adverse 
changes associated with carbohydrate intake, including triglyceride levels, 
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are stronger risk factors for heart disease in women than in men (JAMA 
Internal Medicine, 2010, January 5). 
A relatively small number of patients in each gender group can be 
considered as an important limitation of this study. There was no possibility 
to test the regression model for males and females separately. However, the 
patients’ gender was controlled by the regression model as an independent 
variable. Another limitation is associated with evaluation of triglyceride 
changes as a difference between two measures. Evaluation of 
pharmacokinetics and changes in a longer time interval is a question for the 
further research. 
 
Conclusion: 
A comparison of female and male subsamples revealed no significant 
differences in measures regarding changes in triglycerides. Therefore, the 
study provides no evidence for differences in a toxic effect between sexes. 
The higher cisplatin dose and higher body fat mass are significant predictors 
for an increase in the triglyceride level. Considered to be among 
thecardiovascularrisk factors, increasing triglycerides are particularly 
important for oncology patients with overweight and cardiac co-morbidities. 
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